Maxim Pharmaceuticals About
Maxim Pharmaceuticals Maxim Pharmaceuticals is a biopharmaceutical
company dedicated to developing therapeutic candidates to treat cancer and liver
disease. Using its proprietary live cell high-throughput screening technology
and chemical genetics, Maxim is developing small-molecule apoptosis
inducers to treat cancer.
This program has produced several lead compounds that are advancing to clinical
trials through collaborations or independently. Maxim is also continuing to screen
compound libraries to identify new compounds. Ceplene™, Maxim’s histamine
based drug candidate, administered in combination with IL-2 as a remission maintenance
therapy, demonstrated an improvement in leukemia free survival in one Phase 3
study of Acute Myeloid Leukemia patients compared to patients receiving no treatment,
the current standard of care. Apoptosis
compounds and Ceplene are investigational drugs and have not been approved
by the U.S. Food and Drug Administration or any international regulatory agency.
Ceplene -- Advanced Melanoma, Acute
Myeloid
Leukemia, Renal Cell Carcinoma, Hepatitis
C MX8899 -- Oral Mucositis, Radiation Dermatitis More
on Maxim